GO
Loading...

Pharmaceuticals

More

  • LONDON, Oct 27- Drugmakers sprinting to develop Ebola vaccines face a series of technical hurdles if they are to get millions of doses ready for use next year-- even assuming clinical trials are successful. The challenges include finding sufficient sterile capacity for filling and packaging finished vials, getting fast quality approvals from regulators, and...

  • Oct 24- Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder. Other approved hemophilia B treatments include Baxter's Rixubis, Pfizer Inc's Benefix and CSL Behring Ltd's Mononine. Baxter's shares were up about 1 percent at $69.66 in early...

  • Valeant: Willing to raise Allergan bid to $200/share Monday, 27 Oct 2014 | 10:37 AM ET
    A doctor draws Allergan Inc. Botox into a syringe before administering it to a patient at the offices of Marcus Facial Plastic Surgery in Redondo Beach, California

    "We are confident that an increase in our stock price, and in consideration, will provide that value," said Valeant CEO.

  • Oct 27- Pfizer Inc ended an agreement with Pain Therapeutics Inc to develop and market Durect Corp's pain drug, Remoxy, sending the stocks of the two smaller drugmakers plummeting. Durect's shares fell as much as 46 percent in early trading on Monday, while Pain Therapeutics stock slumped 61 percent. Pain Therapeutics, which since 2002 has the license to develop...

  • BUSINESS-NEWS-SCHEDULE AT 1330 GMT /9.30 AM ET Monday, 27 Oct 2014 | 10:08 AM ET

    MILAN- Italy's Monte dei Paschi di Siena is likely to try to plug a capital shortfall uncovered by Europe- wide stress tests through asset sales and possibly another cash call, but longer term a takeover could be inevitable. LONDON- Europe's banking healthcheck showed countries and lenders are implementing global capital rules at vastly different speeds, and...

  • Investors see generous profits in obesity epidemic Monday, 27 Oct 2014 | 9:42 AM ET

    With some 84 million people in the U.S. struggling with obesity, investing in obesity stocks has become a Wall Street trend.

  • Boy hospitalized in NYC for possible Ebola symptoms Monday, 27 Oct 2014 | 9:36 AM ET

    The 5-year-old arrived in New York from Guinea and had a 103 degree fever, according to media reports.

  • New test can spot Ebola in 30 minutes: Report Monday, 27 Oct 2014 | 8:23 AM ET

    Researchers say they have developed a test that can diagnose Ebola within 30 minutes, the BBC reports.

  • Checkup on big pharma     Monday, 27 Oct 2014 | 8:15 AM ET

    Barbara Ryan, FTI Consulting, breaks down the numbers on Merck's quarterly results as the company appears to be reaping the rewards of R&D. Also a look ahead to Pfizer's earnings

  • Valeant: We'll bump Allergan offer to $200 a share Monday, 27 Oct 2014 | 7:28 AM ET

    The Canadian drugmaker Valeant said it would be willing to raise its takeover bid for Allergan by almost 12 percent, which would mean $200 or more per share for the maker of Botox. The letter to Allergan's board Monday did not break down the exact terms of the new offer, but Valeant said the increase would consist of added "consideration" and expected appreciation...

  • Drugmakers bet on Ebola vaccines, treatments Sunday, 26 Oct 2014 | 9:31 AM ET

    Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in history. It's unclear who will pay for their products, but companies are betting that governments and aid groups will foot the bill. "The political bet is that the U.S. and World Health Organization have been so embarrassed and burned by this event that they will be...

  • Oct 24- Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder. Obizur will compete with Biogen Idec Inc's Eloctate, which was approved in June. Other approved hemophilia B treatments include Baxter's Rixubis, Pfizer Inc's Benefix and CSL...

  • Baxter's blood disorder drug gets FDA approval Friday, 24 Oct 2014 | 9:35 AM ET

    Oct 24- Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder. The drug, Obizur, has been approved for use in patients with acquired hemophilia A, which usually affects older adults, Baxter said in a statement. The drug will be launched in the United...

  • Pfizer approves $11B stock repurchase plan Thursday, 23 Oct 2014 | 4:32 PM ET

    NEW YORK— Drugmaker Pfizer says it approved the repurchase of $11 billion in company stock. Pfizer has $1.3 billion remaining from its latest stock repurchase program. Pfizer Inc. is the world's second-largest drugmaker, and its products include the vaccine Prevnar and pain and fibromyalgia treatment Lyrica.

  • Drugmakers want indemnity     Thursday, 23 Oct 2014 | 1:38 PM ET

    Drug companies may be looking for legal protection amid a massive demand for Ebola vaccines, reports CNBC's Meg Tirrell.

  • U.S. court upholds patents on Pfizer's cancer drug Thursday, 23 Oct 2014 | 8:57 AM ET

    Oct 23- A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said. Pfizer filed the lawsuit in June 2010 after Mylan attempted to market a generic version of Sutent, patented until 2021.. The case is Pfizer Inc v.

  • Lilly profit plunges as cheaper generics take toll Thursday, 23 Oct 2014 | 7:54 AM ET

    Eli Lilly earnings plunged, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its full-year forecast.

  • Inside Eli Lilly's earnings: CEO     Thursday, 23 Oct 2014 | 7:18 AM ET

    John Lechleiter, Eli Lilly CEO, crunches the numbers on his company's quarterly results and explains how a strong dollar is impacting global sales.

  • Oct 23- Eli Lilly and Co said its quarterly earnings plunged 58 percent, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its earlier full-year profit forecast. The U.S. drugmaker on Thursday said it had earned $501 million, or 47 cents per share, in the third quarter. Sales fell 16 percent to $4.88 billion, but topped...

  • Lilly profit plunges as cheaper generics take toll Thursday, 23 Oct 2014 | 6:50 AM ET

    Oct 23- Eli Lilly and Co said its quarterly earnings plunged 58 percent, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its earlier full-year profit forecast. The U.S. drugmaker on Thursday said it had earned $501 million, or 47 cents per share, in the third quarter. Sales fell 16 percent to $4.88 billion, but topped...